A Multicenter, Prospective, Single-arm Clinical Study of Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)

To investigate the safety and efficacy of the CVA regimen, composed of Chiglitazar Sodium in combination with Venetoclax and Azacitidine, in the treatment of patients with refractory/relapsed acute myeloid leukemia (R/R AML).

开始日期2025-03-15

申办/合作机构

厦门大学附属第一医院（厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所）

ChiCTR2500097595

/ Suspended临床2期IIT

A multicenter, prospective, single-arm clinical study on the treatment of refractory/relapsed acute myeloid leukemia (R/RAML) with Chiglitazar Sodium combined with Venetoclax and Azacitidine(CVA)

开始日期2025-02-28

申办/合作机构

厦门大学附属第一医院（厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所）

100 项与西格列他钠相关的临床结果

登录后查看更多信息

100 项与西格列他钠相关的转化医学

登录后查看更多信息

100 项与西格列他钠相关的专利（医药）

登录后查看更多信息

234

项与西格列他钠相关的文献（医药）

2025-09-01·DIABETES & METABOLISM

The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study

Article

作者: Wang, Yufan ; Peng, Yongde ; Ma, Yunqin ; Tan, Yijiong ; Qu, Wenjun ; Zhao, Jiehua ; Gao, Hong ; Liu, Fang ; Zhen, Qin ; Zhang, Qidi ; Fan, Nengguang

AIM:

To evaluate the efficacy of chiglitazar, a novel pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes (T2D) in a real-world clinical setting.

MATERIALS AND METHODS:

This prospective cohort study included T2D patients with MASLD who received either chiglitazar or other glucose-lowering medications over a 24-week period. To minimize selection bias, 1:1 propensity score matching (PSM) was implemented. The primary outcomes were changes in controlled attenuation parameter (CAP, measuring hepatic steatosis) and liver stiffness measurement (LSM, assessing fibrosis). Secondary outcomes included glycemic parameters and liver enzymes.

RESULTS:

A total of 235 T2D patients were enrolled (40 chiglitazar users, 195 non-chiglitazar users), and 31 matched pairs were derived after 1:1 PSM. The adjusted mean reduction in CAP from baseline to 24 weeks was significantly greater in the chiglitazar group (-28.38 dB/m [95 % CI:36.11;-20.65]) compared to the non-chiglitazar group (-16.74 dB/m [-24.47;-9.01]), with a between-group difference of -11.64 dB/m (-22.38;-0.90, P = 0.038). LSM changes were similar between groups (difference in LS mean:0.11 [-1.04;0.82], P = 0.813). Subgroup analyses indicated that the beneficial effect of chiglitazar was consistent across variables such as sex, age, body mass index, and concomitant use of SGLT-2 inhibitors or GLP-1 receptor agonists (all P for interaction > 0.05).

CONCLUSIONS:

Chiglitazar administration is associated with a significant reduction in CAP values in T2D patients with MASLD, suggesting its potential as a dual therapeutic approach for both conditions.

2025-06-01·JOURNAL OF BODYWORK AND MOVEMENT THERAPIES

Effect of adding global postural reeducation to kendall exercises for treating asymptomatic forward head posture: A single-blinded randomized controlled trial

Article

作者: Yamany, Abeer Abdelrahman ; Abu El Kasem, Shimaa T ; Aneis, Yasser M ; Abu-Taleb, Walaa

INTRODUCTION:

Forward head posture (FHP) is a common postural malalignment in young population that is associated with limitation of mobility and functional disability. Kendall exercises are one of the commonly used postural correction techniques to treat FHP. Global postural reeducation (GPR) is a postural correction exercise commonly used for musculoskeletal disorders. The current study aimed to investigate the combined effect of GPR and Kendall Exercises in the treatment of FHP.

METHODS:

A single-blinded parallel-groups randomized controlled trial was conducted. Forty-three participants aged 18-30 years were recruited with FHP marked by a craniovertebral angle (CVA) less than 50°. Participants were randomly allocated into two groups: group A (GrA) received GPR plus Kendall Exercises, and group B (GrB) received Kendall Exercises only. Variables were measured before and immediately after 12 sessions of treatment including CVA, gaze angle (GA), shoulder angle (SA), cervical range of motion (CROM), neck disability index (NDI), chest expansion, and spinal mobility.

RESULTS:

Between groups analysis revealed no statistically significant difference between either treatment in CVA, CROM, and NDI. There was a statistically significant improvement of chest expansion and spinal mobility in favor to GrA. Within-group analysis revealed that both interventions were statistically significant in improving CVA, CROM, and NDI (P < 0.05). Both treatments showed no statistical difference in GA and SA.

CONCLUSIONS:

The added effect GPR technique to Kendall exercises significantly improved craniovertebral angle, cervical mobility and functional disability, chest expansion, and spinal mobility in people with FHP.

2025-05-04·JOURNAL OF ASTHMA

Comparison of airway inflammation characteristics detected by lower exhaled nitric oxide in cough variant asthma, non-asthmatic eosinophilic bronchitis, and classic asthma

Article

作者: Chen, Qiang ; Zhang, Mengru ; Qiu, Zhongmin ; Aierken, Alimire ; Zhang, Li ; Dong, Ran

OBJECTIVE:

To investigate the inflammatory profiles of non-asthmatic eosinophilic bronchitis (NAEB), cough variant asthma (CVA), and classic asthma (CA) using fractional exhaled nitric oxide (FeNO) analysis to identify their unique inflammatory phenotypes.

METHODS:

This study involved cough patients newly diagnosed, corticosteroid-naïve with CVA (n = 68), NAEB (n = 53), and CA (n = 49). FeNO measurements at exhalation flow rates of 50 mL/s (FeNO₅₀) and 200 mL/s (FeNO₂₀₀) were conducted. The concentration of alveolar nitric oxide (CaNO) was calculated using a two-compartment model. Inflammatory mediators in induced sputum were also analyzed across the groups.

RESULTS:

Significant differences in FeNO₅₀, FeNO₂₀₀, and CaNO levels were observed among the three groups (all p < 0.001). Compared to NAEB, CVA patients demonstrated significantly higher FeNO₅₀ levels (27.5 [interquartile range, IQR: 12.0-33.0] ppb vs. 16.0 [IQR: 12.5-22.0] ppb; p = 0.008) but lower CaNO levels (2.6 [IQR: 1.0-4.3] ppb vs. 3.7 [IQR: 2.3-6.1] ppb; p = 0.009). CA exhibited the highest levels of FeNO₅₀, FeNO₂₀₀, and CaNO compared to both NAEB and CVA (all p < 0.01). In CVA, FeNO₅₀ positively correlated with sputum eosinophils, IL-4, and LTC4, whereas NAEB showed elevated CaNO levels with higher sputum eosinophils, IL-5, and PGE2 (all p < 0.05).

CONCLUSIONS:

Inflammation predominantly affects the central airways in CVA and the peripheral airways in NAEB, with a more uniform distribution across the airway in CA. These discrepancies in airway inflammation may suggest distinct cough mechanisms in CVA, NAEB, and CA.

117

项与西格列他钠相关的新闻（医药）

2025-07-27

·深圳微芯生物科技股份有限公司

世界肝炎日丨糖肝共病隐患多，同防共治看我的

7月28日，是第15个“世界肝炎日”，今年肝炎日的主题直指“社会共治，消除肝炎”。当前，糖尿病与脂肪肝的共病问题已成为全球公共卫生领域的关键挑战。数据显示，全球脂肪肝疾病负担显著增加，代谢相关脂肪性肝病的全球患病率超过35%。随着肥胖和2型糖尿病发病率的增加，预计到2040年，脂肪肝的患病率将增加到55%[1] 。2型糖尿病与脂肪肝共病会显著加剧心血管事件、肝硬化及全因死亡的风险。据统计，中国2型糖尿病人群中，脂肪肝的患病率为55.3%[2]，其中近半数已进展至代谢相关脂肪性肝炎（MASH）阶段。糖肝共管，已刻不容缓。代谢乱局：当糖和肝开启“互相伤害”模式糖尿病与脂肪肝有着共同的致病基础，且会陷入“死循环”。2型糖尿病会促进脂肪肝的进展，并加剧肝细胞损伤，使脂肪肝进一步发展为肝炎和不可逆转的肝硬化，甚至增加肝癌的风险[3]。脂肪肝→纤维化→肝硬化的渐进恶化过程另一方面，脂肪肝使血糖控制更加困难，也会提高心血管疾病、肾损伤等并发症的风险。复杂的病理循环下，传统的诊疗模式有点力不从心了，比如：1看血糖的不管肝，看肝的不管糖，两边都治不彻底。2药物搭配“打架”，降糖药可能伤肝，保肝药未必控糖。3对患者来说，每天吃一把药片，副作用反应叠加，坚持治疗成了不小的挑战诊疗指南指出，脂肪肝的治疗需要多学科协作。减体重、缩腰围、改善胰岛素抵抗、防治代谢综合征和糖尿病、缓解代谢相关脂肪性肝炎和逆转纤维化是主要的治疗对策[4]。西格列他钠：PPAR协同效应破解困局西格列他钠（双洛平）作为全球首个获批上市的PPAR全激动剂，能够适度激活PPARα、γ、δ三个亚型受体，实现糖、脂、能量代谢的平衡，直击胰岛素抵抗。激活PPAR γ可调节肝脏、脂肪和肌肉的胰岛素敏感性，改善糖代谢。激活PPAR α可促进肝脏和肌肉的脂肪酸氧化，减少肝脏脂质沉积，同时减轻肝脏炎症。激活PPAR δ可增强脂肪和肌肉的能量消耗，同时减少炎症和维护代谢稳定。西格列他钠通过在脂肪组织、肝脏和肌肉中构建代谢调控网络，可同时降低血糖、调节血脂、减少肝脏脂肪变性，并抑制炎症纤维化进程，是目前市场上唯一可“PPARα、γ和δ三型协同，调控代谢稳态平衡”的创新药物。创新答卷：从控糖到护肝的临床实践2021年，西格列他钠获批用于治疗2型糖尿病；2023年被纳入国家医保目录；2024年，获批与二甲双胍联用，覆盖单药及联合用药的治疗场景，并在糖肝共管领域持续取得突破。临床显示，西格列他钠可从降低肝脏脂肪含量、减轻肝脏炎症、缓解肝脏纤维化三方面共同实现肝脏保护。 2型糖尿病合并代谢相关脂肪性肝病2025年6月，一项真实世界研究在法国糖尿病研究学会官方期刊《Diabetes & Metabolism》发表。研究表明，西格列他钠能显著降低共病患者的肝脂肪含量，CAP值下降28.38dB/m[5]。2型糖尿病合并代谢相关脂肪性肝炎2025年3月，一项2型糖尿病合并代谢相关脂肪性肝炎高风险人群的临床研究在亚太区肝病学会年会公布。数据显示，西格列他钠可明显改善肝脏健康[6]。单药治疗代谢相关脂肪性肝炎2024年11月，西格列他钠单药治疗代谢相关脂肪性肝炎的II期临床研究结果入选第75届美国肝脏研究学会年会口头报告。临床试验数据显示，患者肝脏脂肪含量最高下降40%；超70%患者肝酶恢复正常；肝脏硬度值降幅为2kPa[7]。西格列他钠已被纳入第十版《内科学》教材，并获《中国糖尿病防治指南（2024 版）》《胰岛素抵抗相关临床问题专家共识（2022版）》《超重/肥胖多囊卵巢综合征患者体重管理内分泌专家共识（2025版）》推荐。截至2024年，西格列他钠已覆盖全国近2800家医疗机构和3722家药店，患者可及性不断提高。面对“糖尿病-脂肪肝-代谢共病”的连锁反应，世界肝炎日倡导“社会共治”恰逢其时。但唯有药物创新、医疗体系和公众意识拧成一股绳，构建以患者为中心的“代谢健康生态圈”，消除肝炎的路上，我们才能走得更稳更远。凭借独特的创新机制，西格列他钠正用扎实的临床证据推动“糖肝共管”理念落地，用一粒药解多个难题，让患者少跑医院、少吃药，真正实现“控糖护肝两不误”。参考文献：[1]. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2diabetes[J]. Clin Gastroenterol Hepatol, 2024, 22(10):1999‑2010.e8. DOI: 10.1016/j.cgh.2024.03.006.[2]. Xia M, Sun X, Zheng L, et al. Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. BMJ Open Diabetes Res Care. 2020 Jun;8(1):e001311.[3]. Qi X, Li J, Caussy C, et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2024. DOI: 10.1097/HEP.0000000000000913.[4]. 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].中华肝脏病杂志,2024,32(5):418-434.[5]. Tan, Yijiong et al. "The Impact of Chiglitazar, a Pan-Ppar Agonist, on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes: a Real-World Study",Diabetes & metabolism 51.5 (2025)[6]. Pan-PPAR agonist Chiglitazar for the treatment of high-risk MASH patients coexist T2DM: a randomized, double-blind, placebo-controlled study.[7]. Hong You, et al. A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of Chiglitazar in NASH patients (CINAR Study).[8]. Ji L, Song W, Fang H, et al. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing). 2021 Aug 15;66(15):1571-1580.[9]. Jia W, Ma J, Miao H, et al. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing). 2021 Aug 15;66(15):1581-1590[10]. 评价西格列他钠联合二甲双胍治疗经二甲双胍单药控制不佳的2型糖尿病患者的疗效与安全性的随机、双盲、安慰剂平行对照的III期临床试验（RECAM）.1.本文所有内容仅供交流及分享，不可被视作治疗建议。2.微芯生物不推荐任何未获批的药品和/或适应症使用。3.不同个体的治疗方案和用药获益存在差异，如有不适，应及时就医并遵从医疗卫生专业人士的意见与指导。往期推荐当代年轻人，有多脆皮当爸的年纪，要小心一件事瘦不下来？可能是胰岛素抵抗

上市批准临床研究

2025-07-27

·医药经济报

药明康德、翰宇药业、微芯生物中报业绩飘红，亮点几何

A股上市公司半年报业绩预告接连披露，据不完全统计，截至7月23日，A股创新药板块80家企业中，17家已发布中报预告，至少10家创新药企净利润预增超100%。其中，药明康德以超85亿元净利润领跑；翰宇药业依靠技术平台实现国际突围，净利润大增1664％；微芯生物则借创新药商业化放量扭亏。全链协同势能2025年上半年，翰宇药业业绩实现同比扭亏为盈，终结了此前连续多年扣非净利润亏损的局面。根据其半年度业绩预告，净利润同比增超16倍的核心原因是报告期内公司主要的营业收入来源于国际业务，受益于全球市场需求的持续增长、2024年12月23日公司向FDA申报的利拉鲁肽注射液获得批准证书并实现销售、原料药出口持续放量、公司产品的市场竞争力以及严格的成本控制等多重因素，国际业务的营业利润率较高，进一步推动了公司整体盈利水平的提升。同样得益于国际市场红利的还有药明康德。据其披露的业绩预告，归属于本公司股东的净利润同比增长约101.92%。药明康德的盈利增长主要受益于全球医药外包服务需求回升及多肽/寡核苷酸业务爆发式增长，GLP-1减肥药及ADC药物研发热潮推动订单激增。在全球医药研发外包市场持续扩张的背景下，药明康德凭借其在国际市场的强大竞争力和业务布局，实现了业绩的大幅增长。“今年上半年，创新药企业绩增长是政策红利、技术突破、国际化布局及产业链协同作用的结果。”祥峰投资合伙人刘天然告诉《医药经济报》记者。据记者不完全统计，2025年上半年中国创新药领域BD交易超过50起，披露的合作总金额超过480亿美元，同比增幅超过50%。通过技术授权分享全球市场红利、深度参与国际分工，成为中国创新药行业的一大趋势。重视迭代创新尽管不少创新药企业绩表现强劲，但行业洗牌趋势明显。东方财富Choice数据显示，按预告净利润下限统计，共有42只医药股预计2025年上半年将出现亏损。在中国药科大学产业教授、南京济群医药科技股份有限公司董事长李战看来，创新药领域同质化竞争日益凸显，尤其是在热门靶点如GLP-1等领域研发扎堆，可能引发价格战。以利拉鲁肽为例，翰宇药业虽然凭借首仿优势获得先机，但随着更多企业加入，市场竞争格局可能发生变化。“企业要重视迭代式创新。”李战认为，创新药投资窗口期，企业应当对疾病领域和研究动态保持敏锐洞察。刘天然建议企业关注三个方面：一是独特靶点，中国正从fast-follow向全球创新过渡，靶点独特性及科研、临床概念验证至关重要；二是技术“护城河”，即使靶点不够独特，也要提前布局技术迭代方向，进入下一波竞争；三是临床未满足需求，考虑其他靶点或机理药物的竞争，评估市场商业化空间。来自支付端的支持也至关重要。微芯生物净利润增长主要源于核心产品销量提升及战略调整见效。据半年度业绩预告，公司产品西达本胺弥漫大B细胞淋巴瘤适应症新进医保，西格列他钠销售策略优化且“糖肝共管”独特优势得到市场认可，两款产品销量大幅增长。编辑：范晓艳版式编辑：余远泽审校：马飞、张松真创新获更强支持，集采将优化价差计算锚点，商保创新药目录申报量已过百允许按品牌报量，第十一批国采新规明确18亿并购，1元剥离，国资再度出手，“并购+瘦身”整合持续升温www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

抗体药物偶联物财报寡核苷酸医药出海引进/卖出

2025-07-26

·赛柏蓝

17个品种有望进院，超32亿注射剂在列

编者按：本文来自米内网，作者苍穹；赛柏蓝授权转载；编辑相宜近日，成都市新都区第三人民医院发布公告，17个药品拟通过遴选新增进院，“中化生”领域均有涉及。其中，不乏注射用美罗培南等2024年在中国公立医疗机构终端销售额超32亿元的畅销药，以及西格列他钠片等2023-2025Q1销售额增速均达两位数及以上的潜力品种。17个拟进院的药品以医保用药为主，占据15个席位；从剂型上看，注射剂以6个产品在数量上领跑；治疗大类方面，消化系统及代谢药有3个产品在列，血液和造血系统药物、呼吸系统用药、全身用抗感染药物、肌肉-骨骼系统、杂类各以2个产品位居其后。拟进院新药名单注：带*为独家品种（含剂型独家，下同）注射用美罗培南属于碳青霉烯类抗生素，可用于成人和儿童由单一或多种对美罗培南敏感的细菌引起的感染。在中国公立医疗机构终端，该药2022年销售额达到峰值近70亿元；随后受集采影响，2023-2024年均出现回落至超32亿元；2025Q1止跌回升，以13.37%的增速增长至超8亿元，是全身用抗细菌化药TOP4产品。2025Q1中国公立医疗机构终端全身用抗细菌化药产品TOP5脂肪乳氨基酸(17)葡萄糖(11%)注射液用于不能或功能不全或被禁忌经口/肠道摄取营养的成人患者，目前已纳入国家基药及医保乙类药目录。数据显示，该产品2024年在中国公立医疗机构终端销售规模接近10亿元，同比增长5.87%；2025Q1收获约2.2亿元，从企业格局上看，科伦药业以约40%的市占比首度反超原研厂商费森尤斯卡比（约37%），仿制原研替代效应愈发显著。2025Q1中国公立医疗机构终端脂肪乳氨基酸(17)葡萄糖(11%)注射液企业格局西格列他钠片是微芯生物自主研发和生产的1类独家创新药，用于改善成人2型糖尿病患者的血糖控制。2023年1月，该药经谈判纳入医保后市场快速放量，2023-2025Q1在中国公立医疗机构终端销售额增速分别达2662.58%、321.29%和52.4%。近年来中国公立医疗机构终端西格列他钠片销售趋势（单位：万元）此外，拟遴选进院的药品还包括：治疗急性气管-支气管炎的九味止咳口服液、缓解骨关节炎疼痛的艾瑞昔布片等独家品种，以及注射用盐酸万古霉素、艾普拉唑肠溶片等2024年在中国公立医疗机构终端销售规模超11亿元的大品种，涵盖消化系统及代谢药、全身用抗感染药物、呼吸系统疾病用药等多个治疗大类。资料来源：米内网数据库、成都市新都区第三人民医院等END内容沟通：郑瑶（13810174402）

100 项与西格列他钠相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	中国	成都微芯药业有限公司	2021-10-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰岛素抵抗	临床2期	中国	深圳微芯生物科技股份有限公司	2022-03-21
非酒精性脂肪性肝炎	临床2期	中国	深圳微芯生物科技股份有限公司	2022-03-21
糖尿病	临床1期	中国	深圳微芯生物科技股份有限公司	2015-11-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05193916 (CGZ203, Biospace) 人工标引	临床2期	非酒精性脂肪性肝炎	104	Chiglitazar 48mg	蓋繭鏇淵糧積積淵齋衊(鏇淵齋夢廠廠繭構齋選) = 構廠淵遞糧構壓襯襯餘構蓋遞蓋網顧襯遞襯鏇 (鏇構積願糧顧遞網觸選 ) 更多	积极	2024-10-15
				Chiglitazar 64mg	蓋繭鏇淵糧積積淵齋衊(鏇淵齋夢廠廠繭構齋選) = 鏇鏇憲衊簾襯齋網艱觸構蓋遞蓋網顧襯遞襯鏇 (鏇構積願糧顧遞網觸選 ) 更多
NCT05193916 (CGZ203, PRNewswire) 人工标引	临床2期	非酒精性脂肪性肝炎	-	Carfloglitazar low dose	顧齋夢鏇鹽鏇淵廠膚範(衊襯構蓋鹽構繭壓獵簾) = Preliminary results showed that both dose groups of chiglitazar produced significant and dose-dependent reductions at the primary efficacy endpoint (the proportion of changes from baseline in liver fat content evaluated by MRI-PDFF after 18 weeks of treatment), compared to placebo control group. 範製鏇觸衊廠鬱願繭繭 (齋襯糧醖糧夢願糧積鏇 ) 达到更多	积极	2024-03-18
				Carfloglitazar high dose
NCT04807348 (RECAM study, EASD2023)	临床3期	2型糖尿病追加	533	Chiglitazar 32 mg	網顧衊積窪積餘鏇鑰鹽(製願廠襯鬱顧窪觸糧繭) = 範積鑰蓋膚膚膚壓廠蓋壓醖窪鏇壓餘廠繭繭齋 (齋齋鏇襯繭壓製鹹遞築, -0.60 ~ -0.25) 更多	积极	2023-10-05
				Chiglitazar 48 mg	鏇網衊淵廠鹹願築簾艱(觸醖範鑰製範襯選膚簾) = 顧積憲鏇範鑰觸醖獵鬱鹽築願鹹積願廠夢積遞 (衊蓋壓願構繭憲選糧膚 )
Pubmed \| Sci Bull (Beijing)	临床3期	2型糖尿病	-	Chiglitazar 32 mg	積廠構淵積蓋衊餘醖選(鏇製鹽壓製鬱壓積餘壓) = 蓋醖艱憲醖遞艱蓋範積願醖範製範蓋壓觸鹹鹹 (廠繭艱簾淵齋醖顧築構, -1.10 ~ -0.65)	积极	2021-08-01
				Chiglitazar 48 mg	積廠構淵積蓋衊餘醖選(鏇製鹽壓製鬱壓積餘壓) = 鏇構鹽鏇齋鹽鏇築鹹襯願醖範製範蓋壓觸鹹鹹 (廠繭艱簾淵齋醖顧築構, -1.29 ~ -0.81)
CMAS (Pubmed \| Sci Bull (Beijing))	临床3期	2型糖尿病	-	Chiglitazar 32 mg	鏇築廠築鏇製齋壓衊遞(窪鹹簾憲壓顧壓範鑰淵) = 鬱窪獵鬱簾獵夢鏇壓構遞製衊鑰糧繭獵壓淵衊 (願醖鬱願艱觸襯衊積網 )	积极	2021-08-01
				Chiglitazar 48 mg	鏇築廠築鏇製齋壓衊遞(窪鹹簾憲壓顧壓範鑰淵) = 齋襯鏇艱積獵憲繭獵觸遞製衊鑰糧繭獵壓淵衊 (願醖鬱願艱觸襯衊積網 )
NCT02173457 \| NCT02121717 (not available, EASD2020)	临床3期	2型糖尿病 insulin resistance \| plasma TG \| HOMA-IR ... 更多	1,274	Chiglitazar 32 mg	餘築醖獵壓鹹遞艱鏇願(構鬱壓網夢淵繭築鑰窪) = It suggested a size shift of LDL particles from small dense to less atherogenic larger one 廠鬱醖憲獵願繭鹽膚艱 (夢蓋蓋壓獵鑰齋餘夢壓 ) 更多	积极	2020-09-23
				Placebo
NCT02121717 (CMAP, ADA2019)	临床3期	2型糖尿病	535	Chiglitazar 32 mg	壓鏇齋顧憲鹹艱醖簾淵(積鑰獵餘膚夢構憲築壓) = 糧遞蓋製遞製鹹鑰夢觸鏇窪醖餘製構範憲淵鑰 (鹹鏇鬱鑰淵簾壓衊鹽淵, -1.10 ~ -0.65)	积极	2019-06-01
				Chiglitazar 48 mg	壓鏇齋顧憲鹹艱醖簾淵(積鑰獵餘膚夢構憲築壓) = 積襯繭廠廠艱壓範願襯鏇窪醖餘製構範憲淵鑰 (鹹鏇鬱鑰淵簾壓衊鹽淵, -1.29 ~ -0.81)
NCT02173457 (CMAS, ADA2019)	临床3期	2型糖尿病	739	Chiglitazar 32 mg	顧餘網鬱襯窪範襯構鑰(鹹餘衊鏇鑰襯遞艱夢醖) = 廠憲選鏇鹽顧艱糧製願夢廠窪窪繭夢廠餘憲構 (積積窪鑰淵鬱壓壓鏇遞, -0.22 ~ 0.15)	积极	2019-06-01
				Chiglitazar 48 mg	顧餘網鬱襯窪範襯構鑰(鹹餘衊鏇鑰襯遞艱夢醖) = 繭簾膚壓壓鹽簾顧簾簾夢廠窪窪繭夢廠餘憲構 (積積窪鑰淵鬱壓壓鏇遞, -0.27 ~ 0.10)